Zacks Investment Research upgraded shares of Compugen Ltd. (NASDAQ:CGEN) from a hold rating to a buy rating in a research report sent to investors on Tuesday. Zacks Investment Research currently has $7.00 price target on the stock.
According to Zacks, “Compugen Ltd. is a pioneer in the fields of computational genomics and proteomics. The company combines the disciplines of mathematics and computer science with molecular biology to improve the understanding of genomics and proteomics, the study of genes and proteins. Compugen’s expertise in these areas is used to develop core technologies and platforms that are the basis for its products and services. These products and services are designed to enable life scientists to significantly enhance their research efforts in drug discovery. “
Separately, FBR & Co reiterated a buy rating on shares of Compugen in a research report on Wednesday, June 22nd. Six analysts have rated the stock with a buy rating, Compugen has a consensus rating of Buy and a consensus price target of $10.40.
Compugen (NASDAQ:CGEN) opened at 6.15 on Tuesday. The company has a 50-day moving average of $6.76 and a 200-day moving average of $6.65. Compugen has a 12 month low of $4.32 and a 12 month high of $7.79. The stock’s market cap is $313.08 million.
Compugen (NASDAQ:CGEN) last announced its earnings results on Tuesday, August 2nd. The company reported ($0.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.04. Compugen had a negative net margin of 245.83% and a negative return on equity of 26.46%. On average, equities analysts forecast that Compugen will post ($0.56) EPS for the current fiscal year.
Several institutional investors have recently modified their holdings of the company. Menta Capital LLC raised its position in shares of Compugen by 2.0% in the first quarter. Menta Capital LLC now owns 160,450 shares of the company’s stock worth $895,000 after buying an additional 3,100 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Compugen by 20.9% in the first quarter. Geode Capital Management LLC now owns 22,873 shares of the company’s stock worth $127,000 after buying an additional 3,959 shares in the last quarter. Benjamin F. Edwards & Company Inc. bought a new position in shares of Compugen during the second quarter worth $164,000. Rothschild Investment Corp IL raised its position in shares of Compugen by 2.2% in the second quarter. Rothschild Investment Corp IL now owns 458,510 shares of the company’s stock worth $2,971,000 after buying an additional 10,000 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its position in shares of Compugen by 2.2% in the second quarter. Janney Montgomery Scott LLC now owns 45,787 shares of the company’s stock worth $293,000 after buying an additional 1,000 shares in the last quarter. Hedge funds and other institutional investors own 14.09% of the company’s stock.
Compugen Ltd. (Compugen) is a therapeutic discovery company. The Company focuses on the discovery and development of monoclonal antibodies (mAbs) and therapeutic proteins in the fields of oncology and immunology. Its pipeline program consists of drug targets and therapeutic product candidates at various stages ranging from target validation to pre-clinical studies in the fields of oncology and immunology, with a primary focus on immuno-oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Compugen Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.